Dulaglutide,
does it really help with Lower HbA1c in type 2 diabetes and reduce major adverse cardiovascular events in people at high cardiovascular risk?
research showsDulaglutide is rated A because large randomized evidence shows that it lowers HbA1c in type 2 diabetes and reduces major adverse cardiovascular events in people with cardiovascular disease or risk factors. In REWIND, 9,901 participants followed for a median of 5.4 years had MACE rates of 12.0% versus 13.4%, HR 0.88 (95% CI 0.79 to 0.99; P=0.026). AWARD trials and long-term REWIND analyses consistently confirmed HbA1c lowering. Gastrointestinal adverse effects and risks involving pancreatitis, gallbladder disease, or hypoglycaemia with concomitant therapy are recorded separately under safety.
ads claimMarketing can simplify the medicine into one injection that solves glucose, weight, and cardiovascular risk simultaneously. In practice it is prescription therapy used with diet and exercise; absolute cardiovascular benefit depends on baseline risk, and weight loss is not the core endpoint of this combined claim.
Useful facts when choosing a product
- Dulaglutide is a prescription GLP-1 receptor agonist injected subcutaneously once weekly, and dose selection or escalation should follow the approved label and prescriber instructions.
- The REWIND cardiovascular evidence applies most directly to adults with type 2 diabetes who have established cardiovascular disease or cardiovascular risk factors.
- Nausea, vomiting, diarrhoea, and reduced appetite are common, and severe persistent abdominal pain can require assessment for pancreatitis or gallbladder disease.
- Concomitant insulin or a sulfonylurea can increase hypoglycaemia risk, and the product label should be checked for the rodent thyroid C-cell tumour warning and related contraindications or precautions.
What the research actually shows
REWIND randomized 9,901 participants at 371 sites in 24 countries to dulaglutide 1.5 mg weekly or placebo. Over a median of 5.4 years, first MACE occurred in 594 of 4,949 versus 663 of 4,952 participants, giving HR 0.88. Long-term REWIND analyses found HbA1c lowering across baseline glycaemic ranges, and the 810-participant, 78-week AWARD-2 trial found greater HbA1c reduction with dulaglutide 1.5 mg than with insulin glargine without forced titration. Weight loss was also observed but is secondary to the HbA1c and MACE claim assessed here.
Why this is classified as A (89)
The 9,901-participant REWIND double-blind cardiovascular outcomes trial established superiority on MACE, HR 0.88 (95% CI 0.79 to 0.99; P=0.026), over a median of 5.4 years, and HbA1c lowering was repeated across AWARD trials and long-term REWIND analyses. This is aligned with semaglutide claim 615 at A and is evidentially distinct from tirzepatide claim 914 at C59 after failed MACE superiority. The result is A with 89 points.
Counterpoint. An A efficacy grade does not guarantee the same absolute benefit or safety for every patient. Gastrointestinal tolerance, concomitant medicines, dehydration-related renal risk, pancreatic or gallbladder history, and medullary-thyroid-cancer-related contraindications require individual assessment.
Rejudgment record. New verdict — Reflected prespecified superiority on the direct hard MACE endpoint in the 9,901-participant REWIND trial over a median of 5.4 years (HR 0.88, P=0.026) and repeated HbA1c lowering in AWARD trials; aligned with semaglutide claim 615 at A and distinguished from tirzepatide claim 914 at C59 after failed MACE superiority at P=.09
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduction of major adverse cardiovascular events in higher-risk type 2 diabetes | A | Direct MACE was significantly reduced with HR 0.88 in the 9,901-participant REWIND trial. |
| HbA1c lowering in type 2 diabetes | A | AWARD trials and long-term REWIND data consistently showed lowering across doses and background therapies. |
| Weight reduction | C | This was a consistent secondary effect, but it was a secondary endpoint in manufacturer development trials and not the core endpoint of the combined claim, so it is separately limited to C. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Gerstein HC et al.; REWIND Investigators. 2019 | Multinational multicentre randomized double-blind placebo-controlled cardiovascular outcomes trial | 4 | Funded by Eli Lilly and Company | First composite MACE of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death | 594 of 4,949 versus 663 of 4,952 participants; HR 0.88 (95% CI 0.79 to 0.99; P=0.026). | Key large direct hard-endpoint evidence |
| Giorgino F et al. AWARD-2. 2015 | Seventy-eight-week randomized active-controlled trial | 810 | Eli Lilly development trial with company employees among the authors | Change in HbA1c plus hypoglycaemia, weight, and gastrointestinal adverse events | Once-weekly dulaglutide 1.5 mg produced greater HbA1c reduction than insulin glargine without forced titration. | Direct randomized active-controlled HbA1c evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-21).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Cite this verdict
[Chamgap] Dulaglutide x lower HbA1c and reduce MACE in type 2 diabetes — Evidence Grade A·89. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/dulaglutide-type-2-diabetes-hba1c-mace/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.